Track topics on Twitter Track topics that are important to you
RATIONALE: Monoclonal antibodies, such as cixutumumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving cixutumumab together with temsirolimus may kill more tumor cells.
- To confirm the safety and tolerability of cixutumumab and temsirolimus in patients with castration-resistant metastatic prostate cancer and a rising PSA. (Phase I)
- To determine the tumor response rate and/or composite time to progression in patients treated with this regimen. (Phase II)
- To determine the maximal percent decrease in PSA from baseline.
- To determine the change in PSA doubling time.
- To determine the time to PSA progression and 6-month progression-free survival.
- To determine the rate of adverse events.
- To evaluate changes in circulating tumor cell (CTC) numbers with time.
- To evaluate IGF1R and AR in CTCs and correlate with response.
- To evaluate profiling CTCs at the molecular level by PCR for prostate cancer-specific genes.
- To explore the association between clinical outcomes, administration of therapy, and serial FDG-PET imaging.
- To correlate 18-FDHT-PET imaging findings with outcome measures of response.
- To perform tumor biopsies and evaluate biomarkers that may correlate with active feedback and tumor response to therapy, including anti-IRS-1, anti-IRS-2, pAkt(S473), p70/S6K, anti-phospho-PRAS 40, and PTEN status.
OUTLINE: This is a multicenter study.
Patients receive cixutumumab IV over 60 minutes and temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Patients may undergo imaging and serum and tumor tissue sample collection periodically for correlative laboratory studies.
After completion of study treatment, patients are followed at 4 weeks.
Masking: Open Label, Primary Purpose: Treatment
cixutumumab, temsirolimus, laboratory biomarker analysis
University of Chicago Cancer Research Center
National Cancer Institute (NCI)
Published on BioPortfolio: 2014-08-27T03:17:31-0400
This phase I trial studies the side effects and best dose of cixutumumab and temsirolimus in treating patients with locally advanced or metastatic cancer. Monoclonal antibodies, such as ci...
This phase II trial studies how well cixutumumab and temsirolimus work in treating patients with recurrent or refractory sarcoma. Monoclonal antibodies, such as cixutumumab, can block tumo...
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as cixutumumab, can block tumor growth in dif...
This randomized phase II trial is studying bicalutamide, goserelin, or leuprolide acetate to see how well they work when given with or without cixutumumab in treating patients with newly d...
RATIONALE: Temsirolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Monoclonal antibodies, such as bevacizumab, can block tumor growth in dif...
To determine whether prostate-specific antigen (PSA) could serve as a biomarker for breast cancer.
Prostate cancer is diagnosed in over 1 million men every year globally, yet current diagnostic modalities are inadequate for identification of significant cancer and more reliable early diagnostic bio...
Prostate-specific antigen (PSA) is a biomarker for the diagnosis and management of prostate cancer and involved in the development of prostate cancer and/or its progression from the localized to the m...
Prostate cancer has become one of commonest urologic tumors in male. In recent years, miRNAs are continually attracting attentions of researchers for their special regulatory function in human cancers...
No unambiguous role of the involvement of uroplasminogen activator (uPA) and plasminogen activator inhibitor type-1 (PAI-1) in prostate cancer has emerged, with current evidence suggesting that neithe...
Infiltration of inflammatory cells into the parenchyma of PROSTATE. The subtypes are classified by their varied laboratory analysis, clinical presentation and response to treatment.
A glycoprotein that is a kallikrein-like serine proteinase and an esterase, produced by epithelial cells of both normal and malignant prostate tissue. It is an important marker for the diagnosis of prostate cancer.
A synthetic retinoid that is used orally as a chemopreventive against prostate cancer and in women at risk of developing contralateral breast cancer. It is also effective as an antineoplastic agent.
Tissue ablation of the PROSTATE performed by ultrasound from a transducer placed in the RECTUM. The procedure is used to treat prostate cancer (PROSTATIC NEOPLASMS) and benign prostatic hypertrophy (PROSTATIC HYPERPLASIA).
Proteins secreted by the prostate gland. The major secretory proteins from the human prostate gland include PROSTATE-SPECIFIC ANTIGEN, prostate-specific acid phosphatase, prostate-specific membrane antigen, and prostate-specific protein-94.
In a clinical trial or interventional study, participants receive specific interventions according to the research plan or protocol created by the investigators. These interventions may be medical products, such as drugs or devices; procedures; or change...